File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

TitleNavigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years
Authors
Keywordsartificial intelligence - AI
digital health
gene therapy (GT)
immunoglobulin replacement therapy (IGRT)
inborn errors of immunity (IEI)
patient-reported outcome measures (PROMs)
primary immunodeficiencies (PIDs)
targeted therapies
Issue Date17-Jun-2025
PublisherFrontiers Media S.A.
Citation
Frontiers in Immunology, 2025, v. 16 How to Cite?
AbstractIntroduction: The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration. Methods: This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care. Results: These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years. Discussion: These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient’s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.
Persistent Identifierhttp://hdl.handle.net/10722/369762

 

DC FieldValueLanguage
dc.contributor.authorMamede, Lúcia-
dc.contributor.authorSabà, Roser Cantenys-
dc.contributor.authorVan Coillie, Samya-
dc.contributor.authorPrévot, Johan-
dc.contributor.authorSánchez-Ramón, Silvia-
dc.contributor.authorPoli, Cecilia-
dc.contributor.authorBarasa, Anne-
dc.contributor.authorSchuller, Björn W.-
dc.contributor.authorHendel, Ayal-
dc.contributor.authorGarcelon, Nicolas-
dc.contributor.authorBoersma, Cornelis-
dc.contributor.authorLee, Pamela-
dc.contributor.authorBooth, Claire-
dc.contributor.authorNotarangelo, Luigi D.-
dc.contributor.authorDrabwell, Jose-
dc.contributor.authorRider, Nicholas L.-
dc.contributor.authorStaal, Frank J.T.-
dc.contributor.authorBurns, Siobhan O.-
dc.contributor.authorVan Hagen, Martin-
dc.contributor.authorPergent, Martine-
dc.contributor.authorRivière, Jacques G.-
dc.contributor.authorMahlaoui, Nizar-
dc.date.accessioned2026-01-31T00:35:41Z-
dc.date.available2026-01-31T00:35:41Z-
dc.date.issued2025-06-17-
dc.identifier.citationFrontiers in Immunology, 2025, v. 16-
dc.identifier.urihttp://hdl.handle.net/10722/369762-
dc.description.abstractIntroduction: The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration. Methods: This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care. Results: These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years. Discussion: These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient’s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.-
dc.languageeng-
dc.publisherFrontiers Media S.A.-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectartificial intelligence - AI-
dc.subjectdigital health-
dc.subjectgene therapy (GT)-
dc.subjectimmunoglobulin replacement therapy (IGRT)-
dc.subjectinborn errors of immunity (IEI)-
dc.subjectpatient-reported outcome measures (PROMs)-
dc.subjectprimary immunodeficiencies (PIDs)-
dc.subjecttargeted therapies-
dc.titleNavigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years-
dc.typeArticle-
dc.identifier.doi10.3389/fimmu.2025.1596971-
dc.identifier.scopuseid_2-s2.0-105009715599-
dc.identifier.volume16-
dc.identifier.eissn1664-3224-
dc.identifier.issnl1664-3224-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats